The International Prognostic Index predicts outcome in aggressive adult T-cell leukemia/lymphoma: Analysis of 126 patients from the International Peripheral T-Cell Lymphoma Project

Author(s): Suzumiya J, Ohshima K, Tamura K, Karube K, Uike N, et al.

Abstract

Background

The International Peripheral T-cell Lymphoma Project was organized to better understand the T-cell and natural killer (NK) cell lymphomas, and our task is to present the clinicopathologic correlations and therapeutic results for adult T-cell leukemia/lymphoma (ATL).

Patients and methods

Among 1153 patients with T-cell or NK cell lymphomas, 126 patients (9.6%) with ATL were represented in this project. All were categorized as aggressive ATL, i.e. acute or lymphoma type, and 87% fell into the lymphoma type.

Similar Articles

Cardiotoxicity and cardioprotection in childhood cancer

Author(s): Lipshultz SE, Sambatakos P, Maguire M, Karnik R, Ross SW, et al.

Transcription factor GATA4 inhibits doxorubicin-induced autophagy and cardiomyocyte death

Author(s): Kobayashi S, Volden P, Timm D, Mao K, Xu X, et al.

Clinical cardiotoxicity following anthracycline treatment for childhood cancer: The Pediatric Oncology Group experience

Author(s): Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, et al.

Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer

Author(s): Lipshultz SE, Lipsitz SR, Mone SM, Goorin AM, Sallan SE, et al.

Doxorubicin-induced cardiac toxicity and cardiac rest gated blood pool imaging

Author(s): Aiken MJ, Suhag V, Garcia CA, Acio E, Moreau S, et al.

Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies

Author(s): Wouters KA, Kremer LC, Miller TL, Herman EH, Lipshultz SE

Acute chemotherapy-induced cardiomyopathy treated with intracorporeal left ventricular assist device in an 8-year-old child

Author(s): Schweiger M, Dave H, Lemme F, Cavigelli-Brunner A, Romanchenko O, et al.

Successful bridge to recovery with VAD implantation for anthracycline-induced cardiomyopathy

Author(s): Kurihara C, Nishimura T, Nawata K, Kinoshita O, Hisagi M, et al.

Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia

Author(s): Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, et al.

Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure

Author(s): Palazzuoli A, Gallotta M, Quatrini I, Nuti R

Cardiotoxicity in childhood cancer survivors: strategies for prevention and management

Author(s): Harake D, Franco VI, Henkel JM, Miller TL, Lipshultz SE

Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study

Author(s): Thompson PA, Rosner GL, Matthay KK, Moore TB, Bomgaars LR, et al.